tlr recognition self nucleic acids hampers glucocorticoid activity lupus
glucocorticoids widely used treat patients autoimmune diseases systemic lupus erythematosus sle however regimens used treat many conditions maintain disease control majority sle patients aggressive approaches high-dose methylprednisolone pulse therapy used provide transient reductions disease activity primary anti-inflammatory mechanism glucocorticoids thought nf-kappa b inhibition recognition self nucleic acids toll-like receptors tlr7 tlr9 b cells plasmacytoid dendritic cells pdcs important step pathogenesis sle promoting anti-nuclear antibodies production type interferon ifn correlated severity disease following activation self-nucleic acid-associated immune complexes pdcs migrate tissues demonstrate vitro vivo stimulation pdcs tlr7 can account reduced activity glucocorticoids inhibit ifn pathway sle patients two lupus-prone mouse strains triggering pdcs tlr7 nucleic acid-containing immune complexes synthetic ligands activates nf-kappa b pathway essential pdc survival glucocorticoids affect nf-kappa b activation pdcs preventing glucocorticoid induction pdc death consequent reduction systemic ifn-alpha levels findings unveil new role self nucleic acid recognition tlrs indicate inhibitors tlr7 signalling prove effective corticosteroid-sparing drugs
